-trectinib
Drugs that block TRK kinases, like larotrectinib.
- Drugs ending in -trectinib: 10
- Approved somewhere: 3
- With a US drug page: 3
- Stem
- -trectinib
- Class
- Drugs that block TRK kinases, like larotrectinib
- Sub-stem of
- -tinib: Small molecules that block tyrosine kinases, the switches for many growth signals
- Most common targets
- Neurotrophic tyrosine kinase receptor (4), ROS1 (3), ALK (1), NTRK1 (1), NTRK2 (1), NTRK3 (1), CD74, ROS1 (1), ROS1, SDC4 (1)
Approved and clinical-stage drugs in ChEMBL whose names ending in -trectinib, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Entrectinib | Approved | Neurotrophic tyrosine kinase receptor, ROS1, ALK | Neurotrophic tyrosine kinase receptor inhibitor |
| Larotrectinib | Approved | Neurotrophic tyrosine kinase receptor | Neurotrophic tyrosine kinase receptor inhibitor |
| Repotrectinib | Approved | NTRK1, NTRK2, ROS1, NTRK3 and 2 more | Nerve growth factor receptor Trk-A inhibitor |
| Anizatrectinib | Phase 2 | — | — |
| Boditrectinib | Phase 2 | — | — |
| Emzeltrectinib | Phase 2 | — | — |
| Taletrectinib | Phase 2 | ROS1, Neurotrophic tyrosine kinase receptor | Proto-oncogene tyrosine-protein kinase ROS inhibitor |
| Paltimatrectinib | Phase 1 | — | — |
| Selitrectinib | Phase 1 | Neurotrophic tyrosine kinase receptor | Neurotrophic tyrosine kinase receptor inhibitor |
| Zurletrectinib | Phase 1 | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO